Antoine Leuzy
21 – 30 of 47
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
(
- Contribution to journal › Scientific review
-
Mark
A multicentre validation study of the diagnostic value of plasma neurofilament light
(
- Contribution to journal › Article
-
Mark
Tau PET correlates with different Alzheimer’s disease-related features compared to CSF and plasma p-tau biomarkers
(
- Contribution to journal › Article
-
Mark
Comparing the Clinical Utility and Diagnostic Performance of Cerebrospinal Fluid P-Tau181, P-Tau217 and P-Tau231 Assays
(
- Contribution to journal › Article
-
Mark
The impact of demographic, clinical, genetic, and imaging variables on tau PET status
(
- Contribution to journal › Article
-
Mark
The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations
(
- Contribution to journal › Article
-
Mark
Plasma Phospho-Tau Identifies Alzheimer's Co-Pathology in Patients with Lewy Body Disease
(
- Contribution to journal › Article
-
Mark
Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations
(
- Contribution to journal › Article